The Inaccessibility of Vaccines

Vaccines have been long hailed as being some of the greatest public health interventions for avoiding the spread of infectious diseases, with millions of lives being saved worldwide. From childhood vaccinations to COVID-19 vaccines, their development has transformed public health. However, despite all their life saving capacity, vaccines are unavailable to a large percent of the population worldwide.

Economic barriers contribute to this inaccessibility as the costs of vaccines can be extremely high, especially in middle and low-income countries. Even if vaccines are available, their cost is too expensive for the majority of the population, and public healthcare systems do not have the financial resources to provide them to those who can not afford them. This economic disparity causes issues in vaccine accessibility. Additionally, pharmaceutical firms have control over vaccine prices, and their profit margins or high production costs can drive prices up. This places a financial burden on most countries, particularly those that are underdeveloped. These low-income nations often face difficulties receiving vaccines and distributing them due to the cost of the operation. In order to buy them, many countries buy in bulk but this option is unavailable for countries with lower funding for healthcare, leaving citizens unprotected.

Inaccessibility is not just a matter of cost, it also depends on where the vaccines are being made available. The majority of rural or remote communities, especially those nations with poor infrastructure, struggle to access the vaccines they need. Vaccine distribution requires lots of attention to keep vaccines at the appropriate temperature from creation to use. In regions with weak roads, an inconsistent electricity supply, and inadequate storage facilities, making sure the vaccine remains effective is difficult. Vaccines are weakened and become ineffective if they are not stored in refrigeration. Overall, vaccine access in cities is easier due to better healthcare systems, while rural communities may have to wait for long periods of time or even be left out of distribution all together.

Even where vaccines are available, supply chain problems can lead to extreme shortages. The international vaccine supply chain can become overburdened, especially during health crises. For example, in the case of the COVID-19 pandemic, the delay in vaccine manufacturing occurred due to limited production, intellectual property disputes, and bans on exportation. This prevented people from receiving vaccinations and required the government to dictate which citizens were in the most need for vaccines. Lack of coordination between the government and international organizations can lead to stockouts, where supply does not meet demand. These put vulnerable people at risk of contracting the disease while they wait for supply to once again reach consumer demand.

To make vaccine inaccessibility history, steps need to be taken. Organizations like the World Health Organization (WHO), GAVI, and CEPI have a critical role to ensure that vaccines reach the most vulnerable. Political and global action are needed, however, if inequalities in access are to be addressed. Promoting the local manufacturing of vaccines through the use of technology and knowledge transfer can minimize dependence on expensive foreign vaccines. This also reduces the power of pharmaceutical companies and prevents them from dictating trading prices and stock value. For this to happen though, countries must fight against vaccine misinformation by communication effectively with their citizens and promoting education.